Potency and safety analysis of hemp-derived delta-9 products: The hemp vs. cannabis demarcation problem

Clinical data
ATC code
  • none
Legal status
Legal status
  • N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass447.64 g·mol−1
3D model (JSmol)
  • CC(C=C1)=CC=C1CN2C3=C(CC4=C3SC=C4)C(C(NC5CC(C)CCC5C(C)C)=O)=N2

NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.[1] It has reasonable selectivity for the CB2 receptor subtype, having a CB2 affinity of 0.4nM, and 25x selectivity over the related CB1 receptor.[2]

See also


  1. ^ Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
  2. ^ Hanus LO, Mechoulam R (2010). "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59. doi:10.2174/092986710790980096. PMID 20166928.